Drugs Safety AlertNIH Stops Low-Dose Rivaroxaban Arm in CAPTIVA Trial Over Safety Concerns NIH Stops Low-Dose Rivaroxaban Arm in CAPTIVA Trial Over Safety Concerns Read Post »
Clinical Trails Drugs Safety AlertChugai’s NXT007 Shows Promising Safety During Emicizumab Transition in Ha... Chugai’s NXT007 Shows Promising Safety During Emicizumab Transition in Ha... Read Post »
Health Tidings Policy & AcquisitionsSanofi Closes Dynavax Deal, Expands Presence in Adult Vaccines Sanofi Closes Dynavax Deal, Expands Presence in Adult Vaccines Read Post »
Health Tidings Policy & AcquisitionsChugai Licenses Araris’ AraLinQ® Platform to Advance Next-Generation ADC... Chugai Licenses Araris’ AraLinQ® Platform to Advance Next-Generation ADC... Read Post »
Clinical TrailsGSK’s Arexvy RSV Vaccine Accepted for Review in China GSK’s Arexvy RSV Vaccine Accepted for Review in China Read Post »
Health TidingsFDA Issues Refusal-to-File Letter for Moderna’s mRNA-1010 Flu Vaccine FDA Issues Refusal-to-File Letter for Moderna’s mRNA-1010 Flu Vaccine Read Post »
Clinical TrailsAstraZeneca Advances Oral GLP-1 Elecoglipron Toward Phase III AstraZeneca Advances Oral GLP-1 Elecoglipron Toward Phase III Read Post »
Food Health TidingsFDA Initiates Priority Safety Review of BHA Used in Foods FDA Initiates Priority Safety Review of BHA Used in Foods Read Post »
Clinical TrailsKyowa Kirin Takes Full Global Control of Rocatinlimab After Amgen Exit Kyowa Kirin Takes Full Global Control of Rocatinlimab After Amgen Exit Read Post »
Policy & Acquisitions ResearchMexico Partners with Moderna to Boost mRNA Manufacturing and Preparedness Mexico Partners with Moderna to Boost mRNA Manufacturing and Preparedness Read Post »
Health TidingsIambic, Takeda Team Up on AI-Driven Small Molecule Discovery Iambic, Takeda Team Up on AI-Driven Small Molecule Discovery Read Post »
Clinical TrailsTakeda Announces FDA Acceptance of Oveporexton NDA for NT1 Takeda Announces FDA Acceptance of Oveporexton NDA for NT1 Read Post »
Health TidingsAstellas Pharma Inc. Settles U.S. Patent Litigation with Lupin Limited Over... Astellas Pharma Inc. Settles U.S. Patent Litigation with Lupin Limited Over... Read Post »
Health TidingsFDA Issues CRL for REGENXBIO’s RGX-121 in MPS II FDA Issues CRL for REGENXBIO’s RGX-121 in MPS II Read Post »
Health TidingsNovo Nordisk Files Semaglutide Lawsuit Against Hims Novo Nordisk Files Semaglutide Lawsuit Against Hims Read Post »
Policy & AcquisitionsLilly’s $2.4 Billion Orna Deal Signals Push into In Vivo CAR-T Therapies Lilly’s $2.4 Billion Orna Deal Signals Push into In Vivo CAR-T Therapies Read Post »
Clinical TrailsRoche’s Fenebrutinib Meets Phase III Endpoint in PPMS Roche’s Fenebrutinib Meets Phase III Endpoint in PPMS Read Post »
Health TidingsEisai and Biogen Secure Priority Review in China for Subcutaneous LEQEMBI Eisai and Biogen Secure Priority Review in China for Subcutaneous LEQEMBI Read Post »
Health TidingsSanofi’s Rilzabrutinib Gains FDA Breakthrough Therapy Designation, Ja... Sanofi’s Rilzabrutinib Gains FDA Breakthrough Therapy Designation, Ja... Read Post »
Clinical TrailsJohnson & Johnson Reports Results from OMNY-AF Study in A-Fib Johnson & Johnson Reports Results from OMNY-AF Study in A-Fib Read Post »
New Drug ApprovalGSK’s Nucala Secures European Approval for Eosinophilic COPD GSK’s Nucala Secures European Approval for Eosinophilic COPD Read Post »
Food Health TidingsUK Probes 36 Infant Illness Reports Linked to Recalled Infant Formula UK Probes 36 Infant Illness Reports Linked to Recalled Infant Formula Read Post »
Health TidingsFrom Launch to Halt: Hims & Hers’ Semaglutide Reversal From Launch to Halt: Hims & Hers’ Semaglutide Reversal Read Post »
Clinical TrailsFDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label FDA Lifts Prior PCNSL Use Limitation from Gilead’s Yescarta Label Read Post »
Health TidingsPfizer Backs TrumpRx, Reduce Drug Prices in the U.S. Pfizer Backs TrumpRx, Reduce Drug Prices in the U.S. Read Post »
Health TidingsFibrobiologics Fetches Canadian Patent for Cachexia in Chronic Diseases Fibrobiologics Fetches Canadian Patent for Cachexia in Chronic Diseases Read Post »
Health TidingsTrumpRx.gov Goes Live, Drug Pricing and Policy in One Platform TrumpRx.gov Goes Live, Drug Pricing and Policy in One Platform Read Post »
Clinical TrailsDenali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Denali Therapeutics Highlights ETV Platform Progress at WORLDSymposium 2026 Read Post »
Clinical TrailsPfizer’s HYMPAVZI Secures FDA Priority Review for Kids Pfizer’s HYMPAVZI Secures FDA Priority Review for Kids Read Post »
Health TidingsEisai and Biogen Report Growing Real-World Use of Leqembi in Early Alzheime... Eisai and Biogen Report Growing Real-World Use of Leqembi in Early Alzheime... Read Post »
Health TidingsFDA Takes Aim at Non-Approved Compounded GLP-1 Drugs FDA Takes Aim at Non-Approved Compounded GLP-1 Drugs Read Post »
Drugs Safety AlertFDA Revises Capecitabine and 5-FU Labels to Address DPD Deficiency Risk FDA Revises Capecitabine and 5-FU Labels to Address DPD Deficiency Risk Read Post »
Clinical TrailsFDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... FDA Grants Orphan Drug Designation to Zenocutuzumab for NRG1-Fusion Cholang... Read Post »
Health TidingsNovo Nordisk Accuses Hims & Hers of Illegal Semaglutide Compounding, Ci... Novo Nordisk Accuses Hims & Hers of Illegal Semaglutide Compounding, Ci... Read Post »
Clinical TrailsBayer’s Asundexian Cuts Stroke Risk 26% in Phase III Bayer’s Asundexian Cuts Stroke Risk 26% in Phase III Read Post »
Health TidingsBMS and J&J Rethink Anticoagulation with Factor Xia BMS and J&J Rethink Anticoagulation with Factor Xia Read Post »
Health TidingsSimcere Doses First Patient in Anti-Stroke SIM0811 Trial Simcere Doses First Patient in Anti-Stroke SIM0811 Trial Read Post »
Food Policy & AcquisitionsNo to Artificial Colors, Yes to Natural Alternatives: What the New FDA Poli... No to Artificial Colors, Yes to Natural Alternatives: What the New FDA Poli... Read Post »
New Drug ApprovalFDA Approves VYBRIQUE as First Oral Film for Erectile Dysfunction FDA Approves VYBRIQUE as First Oral Film for Erectile Dysfunction Read Post »
New Drug ApprovalAbbVie Seeks FDA, EMA Approval of RINVOQ in Vitiligo AbbVie Seeks FDA, EMA Approval of RINVOQ in Vitiligo Read Post »
Health TidingsEli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Eli Lilly Q4 2025: Mounjaro and Zepbound Fuel 43% Growth Read Post »
Clinical TrailsUCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... UCB’s BIMZELX Achieves 3-Year HS Control: BE HEARD Trial Data Reveale... Read Post »
Clinical TrailsFDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease FDA Fast Tracks Cumberland’s Ifetroban for DMD Heart Disease Read Post »
Clinical TrailsAstellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Astellas Fezolinetant Cuts Menopausal VMS in Japan Phase 3 Read Post »
Clinical TrailsImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma ImmunityBio Launches Phase 2 ResQ215B Trial for Indolent B-Cell Lymphoma Read Post »
Health TidingsValneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Valneva and Butantan Start IXCHIQ Chikungunya Vaccination Pilot in Brazil Read Post »
ResearchJohnson & Johnson Calls Out Surgeon Mental Health Crisis Johnson & Johnson Calls Out Surgeon Mental Health Crisis Read Post »
Health TidingsNovo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Novo Nordisk Reports 10% Sales Growth in 2025 as Wegovy Pill Launch Strengt... Read Post »
Clinical TrailsNovo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Novo Nordisk’s CagriSema Outperforms Semaglutide in REIMAGINE 2 Trial Read Post »
Health TidingsSPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher SPARC’s Sezaby Approval Unlocks Rare Pediatric Priority Review Voucher Read Post »
